Last Updated : April 29, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received Sort descending | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Trodelvy | sacituzumab govitecan | HR+, HER2− advanced or metastatic breast cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Myalepta | metreleptin | Leptin deficiency in lipodystrophy | Active | |||
| Rezurock | belumosudil | Graft-versus-host disease | Reimburse with clinical criteria and/or conditions | Active | ||
| Beqvez | fidanacogene elaparvovec | Hemophilia B | Reimburse with clinical criteria and/or conditions | Active | ||
| Slynd | drospirenone | Contraceptive, oral | Reimburse with clinical criteria and/or conditions | Active | ||
| Nurtec ODT | rimegepant | Migraine, prevention | Withdrawn | |||
| Lonsurf | trifluridine and tipiracil | Metastatic colorectal cancer | Reimburse with clinical criteria and/or conditions | Active | ||
| Talzenna | talazoparib | Metastatic castration-resistant prostate cancer (mCRPC) | Suspended | |||
| Eylea HD | aflibercept 8mg/0.07mL | macular degeneration, age related | Active | |||
| Uplizna | inebilizumab | Neuromyelitis optica spectrum disorders (NMOSD) | Reimburse with clinical criteria and/or conditions | Active |
Last Updated : April 29, 2024